장마감
로그인 회원가입
PAHC
PAHC
Phibro Animal Health Corp
7월 27일 4:00 PM ET (한국 7/28 05:00)
$35.24
+1.21 ▲ +3.54%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$35.24
+0.00 +0.00%

피브로 애니멀 헬스 그룹(PAHC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$1.4B
스몰캡
P/E
15.1
적정 수준
배당수익률
1.36%
52주 위치
28%
저점 +38% · 고점 -41%
애널리스트
보유
B
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 소형주
수익성 ⓘ
Top 26%
성장 ⓘ
Top 46%
밸류에이션 ⓘ
Top 48%
재무 안정 ⓘ
Top 31%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 15원. Over the past 5년, it usually traded around 21원. Not because the price dropped, but because earnings grew much faster — this is one of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ RUTP/E ⓘ 15.14EPS (ttm) ⓘ 2.33Insider Own ⓘ 48.55%Shs Outstand ⓘ 21.0MPerf Week ⓘ 6.63%
Market Cap ⓘ 1.43BForward P/E ⓘ 10.54EPS next Y ⓘ 8.8%Insider Trans ⓘ -1.97%Shs Float ⓘ 20.9MPerf Month ⓘ 10.71%
Enterprise Value ⓘ 2.14BPEG ⓘ 0.51EPS next Q ⓘ 0.71Inst Own ⓘ 50.25%Short Float ⓘ 5.84%Perf Quarter ⓘ -36.11%
Income ⓘ 0.10BP/S ⓘ 0.95EPS this Y ⓘ 47.04%Inst Trans ⓘ 4.36%Short Ratio ⓘ 3.35Perf Half Y ⓘ -9.66%
Sales ⓘ 1.50BP/B ⓘ 3.95EPS next 5Y ⓘ 20.8%ROA ⓘ 6.9%Short Interest ⓘ 1.22MPerf YTD ⓘ -5.67%
Book/sh ⓘ 8.92P/C ⓘ 18.46EPS past 3/5Y ⓘ -0.76% 7.45%ROE ⓘ 30.34%52W High ⓘ -41.34% ($60.08)Perf Year ⓘ 20.77%
Cash/sh ⓘ 1.91P/FCF ⓘ 111.94Sales past 3/5Y ⓘ 11.22% 10.12%ROIC ⓘ 8.53%52W Low ⓘ 37.76% ($25.58)Perf 3Y ⓘ 148.17%
Dividend Est. ⓘ $0.48 (1.36%)EV/EBITDA ⓘ 9.13EPS Y/Y TTM ⓘ 199.43%Gross Margin ⓘ 32.29%Volatility(W/M) ⓘ 3.31% 3.82%Perf 5Y ⓘ 46.28%
Dividend TTM ⓘ 0.48EV/Sales ⓘ 1.43Sales Y/Y TTM ⓘ 25.98%Oper. Margin ⓘ 12.25%ATR (14) ⓘ 1.34Perf 10Y ⓘ 64.9%
Dividend Ex-Date ⓘ 2026/6/3Quick Ratio ⓘ 1.26EPS Q/Q ⓘ 14.14%Profit Margin ⓘ 6.35%RSI (14) ⓘ 60.12Recom ⓘ 2.8
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.17Sales Q/Q ⓘ 10.27%SMA20 ⓘ 6.09% ($33.22)Beta ⓘ 0.46Target Price ⓘ $45.6
Payout ⓘ 40.46%Debt/Eq ⓘ 2.18Earnings ⓘ 2026/5/6SMA50 ⓘ 8.1% ($32.6)Rel Volume ⓘ 0.4Prev Close ⓘ $34.03
Employees ⓘ 2475LT Debt/Eq ⓘ 2.09EPS/Sales Surpr. ⓘ 6.59% 4.49%SMA200 ⓘ -17.34% ($42.63)Avg Volume(3M) ⓘ 0.36MPrice ⓘ $35.24
IPO ⓘ 2014/4/11Option/Short ⓘ Yes/YesTrades ⓘ 3234Volume ⓘ 144,207Change ⓘ 3.54%
Quarterly earnings trend SEC filings · USD
24.6*
24.9
24.12
25.3
25.6*
25.9
25.12
26.3
Revenue Net income 최근 분기: 매출 $384M (YoY +10%) · 순이익 $24M (YoY +15%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Phibro Animal Health Corp (PAHC) Investment Analysis

What kind of company is Phibro Animal Health Corp?

피브로 애니멀 헬스 그룹(PAHC) 성장주
Healthcare · Drug Manufacturers - Specialty & Generic
Healthcare Stocks

🐄 Phibro Animal Health (PAHC) is a global animal health company that develops, manufactures, and sells animal pharmaceuticals and mineral nutritional supplements for livestock and companion animals. The company primarily focuses on products for food-producing animals such as poultry, swine, cattle, and aquaculture, and has diversified its business to include mineral nutrition and industrial specialty chemical products.

Learn more about Phibro Animal Health Corp →
Market Cap
$1.4B
Approx. KRW 2.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2373
Employees2,475people
IPO2014/04/11
Current Price$35.24 ≈ 48,279원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 6월 3일 (수) 주당 $0.12
🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS +6.6% 매출 +4.5%
🎯 Ex-div 2026년 3월 4일 (수) 주당 $0.12
🔔 Earnings release 2026년 2월 4일 (수) · 장 마감 후 EPS +29.9% 매출 +5.1%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
12.3%
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 8.8% · Top 32%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
6.3%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median -4.6% · Top 18%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
32.3%
✓ 부진
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 57.7% · Bottom 16%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
30.3%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 소형주 Median -37.5% · Top tier
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
6.9%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -21.8% · Top 10%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
8.5%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -25.0% · Top 11%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
2.18
✓ High debt
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 0.36
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.17
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.26
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$45.60
현재가 대비 +29.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
10.54배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.51
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+8.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+20.8%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+18.2%
평균 서프라이즈
2026.05.06
상회
실적 $0.76 · 예상 $0.71 +6.5%
2026.02.04
상회
실적 $0.87 · 예상 $0.67 +29.9%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+47.0%
우수
My positionTop 25%
Low range Average High range
성장주 소형주 Median 16.2% · Top 10%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+8.8%
평균
My positionMid-range
Low range Average High range
성장주 소형주 Median 17.5% · Bottom 25%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+20.8%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 18.9% · Top 38%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-0.8%
평균
My positionMid-range
Low range Average High range
성장주 소형주 Median 8.7% · Bottom 39%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+7.5%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 2.9% · Top 43%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+10.1%
평균
My positionMid-range
Low range Average High range
성장주 소형주 Median 10.4% · Bottom 49%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+10.3%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 7.0% · Top 42%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 22%p over 5 years
PAHC +46.3% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-22.1%p
behind the market
vs Health Care (XLV)
+21.8%p
ahead of the sector average
1-year basis
vs S&P 500
+4.8%p
roughly in line with the market
vs Health Care (XLV)
+1.1%p
roughly in line with the sector average
Rank among peers
5-year return Top 24% Based on 25 peers
1-year return Upper-Mid (42%) Based on 28 peers
Current position within 52-week range
Low (-37.8%p) High (-41.3%p)
Current price is 37.8% above the 52-week low and 41.3% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-52.1%
Annualized volatility
70.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

⚠️
Current diagnosis · 2026-07-27
Overbought zone — short-term pullback possible

Current price $35.24 broke above the upper band ($35.13). Stronger buying than average, but signals short-term overheating. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.235 > Signal -0.094 in positive zone + Hist positive (+0.329). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 60.1 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 97.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Earnings·Vs. Sales, In line with peers on Vs. Assets·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Mid-range
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Mid-range
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
15.14x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic median 20.36x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
10.54x
✓ Fair
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 10.48x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.95x
✓ Fair
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
0.95x
✓ Very cheap
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Top 24% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
9.13x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.45x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
111.94x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.25x · Bottom 1% — expensive within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$45.60 vs. current price +29.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership is broadly stable
Insider modest net selling -2.0% · Institutional net buying +4.4% · Short interest moderate 5.8% · Short interest up +0.5pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-2.0%
Insiders net selling
🏦 Institutions (funds & investors)
+4.4%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 50.3%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 48.5%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 1.2%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
5.8%
Moderate
Healthcare 소형주 Median 11.2%
Past 90 days 📈 +0.5%p increase
Short interest days to cover
3.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 21.0M주
Float (tradable shares) 20.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PAHC

ETFs with the highest weightings · 10 total shown
SAWS
SAWS
AAM Sawgrass US Small Cap Quality Growth ETF
2.47%
$8M
XPH
XPH
State Street SPDR S&P Pharmaceuticals ETF
1.79%
$475M
RZG
RZG
Invesco S&P SmallCap 600 Pure Growth ETF
1.36%
$139M
PILL
PILL
Direxion Daily Pharmaceutical & Medical Bull 3X ETF
1.20%
$21M
AIMS
AIMS
Acuitas Small Cap Active ETF
1.05%
$87M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 1.36%
배당보다 주가 성장에 가까운 비중
Dividend Yield
1.36%
Industry average 1.23%
Dividend Per Share
$0.48
Annualized
Payout Ratio
40%
Share of net income paid as dividends
5-Year Growth
0.0%
Annualized dividend growth
📅 지급월 3월 · 9월 · 11월
📊 총 이력 2014~2026 (47건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.40 +0.0%
2016
$0.40 +0.0%
2017
$0.42 +5.0%
2018
$0.48 +14.3%
2019
$0.48 +0.0%
2020
$0.48 +0.0%
2021
$0.48 +0.0%
2022
$0.48 +0.0%
2023
$0.48 +0.0%
2024
$0.48 +0.0%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 47건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-03-04
$0.120
—
1.16%
2025-11-26
$0.120
—
1.39%
2025-09-03
$0.120
—
1.57%
2025-06-04
$0.120
—
2.50%
2025-03-05
$0.120
—
2.55%
2024-11-27
$0.120
—
2.54%
2024-09-04
$0.120
—
3.05%
2024-06-05
$0.120
—
3.47%
2024-03-05
$0.120
—
3.63%
2023-11-28
$0.120
—
6.19%
2023-09-05
$0.120
—
4.47%
2023-06-06
$0.120
—
3.53%
2023-02-28
$0.120
—
3.82%
2022-11-29
$0.120
—
3.98%
2022-09-06
$0.120
—
3.27%
2022-05-31
$0.120
—
3.12%
2022-03-01
$0.120
—
2.88%
2021-11-23
$0.120
—
2.75%
2021-08-31
$0.120
—
2.47%
2021-06-01
$0.120
—
2.13%
2021-03-02
$0.120
—
2.71%
2020-11-24
$0.120
—
3.06%
2020-09-01
$0.120
—
2.91%
2020-06-02
$0.120
—
2.34%
2020-03-03
$0.120
—
2.35%
2019-11-26
$0.120
—
2.46%
2019-09-03
$0.120
—
2.84%
2019-06-04
$0.120
—
1.87%
2019-03-05
$0.120
—
1.85%
2018-11-27
$0.120
—
1.60%
2018-09-04
$0.100
—
0.84%
2018-06-05
$0.100
—
0.87%
2018-03-06
$0.100
—
1.03%
2017-12-05
$0.100
—
1.20%
2017-09-01
$0.100
—
1.37%
2017-05-26
$0.100
—
1.45%
2017-02-27
$0.100
—
1.76%
2016-11-28
$0.100
—
1.78%
2016-09-02
$0.100
—
1.55%
2016-05-27
$0.100
—
2.58%
2016-02-29
$0.100
—
1.81%
2015-11-30
$0.100
—
1.54%
2015-08-31
$0.100
—
1.13%
2015-06-01
$0.100
—
1.15%
2015-03-02
$0.100
—
0.80%
2014-12-01
$0.100
—
0.65%
2014-08-29
$0.100
—
0.52%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 1.2만원
5년 누적 (세후) 5.8만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PAHC PAHC This Stock
$1.4B15.1 ▲4.0 ▼30.34% ▲1.36% ▲+3.5%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
파이브로 애니멀 헬스(PAHC) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
파이브로 애니멀 헬스(PAHC)는 가축·반려동물용 동물 의약품과 미네랄 영양제를 만드는 글로벌 동물 건강 기업으로, 동물 건강 사업 중심의 매출 성장과 인수 기반 사업 확장이 주가와 실적 전망의 핵심 변수로 작용하고 있습니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 피브로 애니멀 헬스 그룹(PAHC)?

피브로 애니멀 헬스 그룹(PAHC) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of PAHC?

The market cap of PAHC is approximately $1.4B, ranking 2,373 within its sector.

Does PAHC pay dividends?

PAHC has a dividend yield of approximately 1.36%, with an annual dividend of $0.48.

What is the P/E ratio of PAHC?

PAHC has a P/E ratio of approximately 15.1x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for PAHC?

PAHC has recorded a 52-week high of $60.08 and a low of $25.58.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.